Clinical trialNCT04995653CompletedPhase 1Interventional

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

SponsorSeres Therapeutics, Inc.Enrollment60Allogeneic Hematopoietic Stem Cell Transplantation

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bina Tejura, MD
Seres Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗
Doris Ponce, MD
MSKCC
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Health - Md Anderson Medical Center
Gilbert, Arizona, United States
Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles - Division of Hematology-Oncology
Marina del Rey, California, United States
Georgetown (medstar Health)
Washington D.C., District of Columbia, United States
University of Florida - Division of Hematology & Oncology
Gainesville, Florida, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Harvard Medical School - Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SER-155SER-155 PlaceboVancomycin PlaceboVancomycin Pre-Treatment

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Nov 2021
Primary completion: 23 Jul 2024
Completion: 23 Jul 2024
Last update posted: 1 Oct 2024
Registered enrollment: 60
Registry id: NCT04995653

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.